» Articles » PMID: 28374110

HTLV-1 Infection and Neuropathogenesis in the Context of Rag1γc (RAG1-Hu) and BLT Mice

Abstract

To date, the lack of a suitable small animal model has hindered our understanding of Human T-cell lymphotropic virus (HTLV)-1 chronic infection and associated neuropathogenesis defined as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The host immune response plays a critical role in the outcome of HTLV-1 infection, which could be better tested in the context of humanized (hu) mice. Thus, we employ here the Balb/c-Rag1γc or Rag1 as well as Bone marrow-Liver-Thymic (BLT) mouse models for engraftment of human CD34 hematopoietic stem cells. Flow cytometry and histological analyses confirmed reconstitution of Rag1 and BLT mice with human immune cells. Following HTLV-1 infection, proviral load (PVL) was detected in the blood of Rag-1 and BLT hu-mice as early as 2 weeks post-infection (wpi) with sustained elevation in the subsequent weeks followed by Tax expression. Additionally, infection was compared between adult and neonatal Rag1 mice with both PVL and Tax expression considerably higher in the adult Rag1 mice as compared to the neonates. Establishment of peripheral infection led to lymphocytic infiltration with concomitant Tax expression and resulting myelin disruption within the central nervous system of infected mice. In addition, up-regulation in the expression of several immune checkpoint mediators such as programmed cell death-1 (PD-1), T-cell Ig and ITIM domain (TIGIT), and T cell Ig and mucin domain-3 protein (Tim-3) were observed on CD8 T cells in various organs including the CNS of infected hu-mice. Collectively, these studies represent the first attempt to establish HTLV-1 neuropathogenesis in the context of Rag-1 and BLT hu-mice as potential novel tools for understanding HTLV-1 neuropathogenesis and testing of novel therapies such as immune checkpoint blockade in the amelioration of chronic HTLV-1 infection.

Citing Articles

Current State of Therapeutics for HTLV-1.

Wang T, Hirons A, Doerflinger M, Morris K, Ledger S, Purcell D Viruses. 2024; 16(10).

PMID: 39459949 PMC: 11512412. DOI: 10.3390/v16101616.


Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.

Mu W, Patankar V, Kitchen S, Zhen A Viruses. 2024; 16(2).

PMID: 38399994 PMC: 10893210. DOI: 10.3390/v16020219.


Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers.

Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P Cancers (Basel). 2021; 13(20).

PMID: 34680208 PMC: 8534156. DOI: 10.3390/cancers13205059.


HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models.

Forlani G, Shallak M, Accolla R, Romanelli M Int J Mol Sci. 2021; 22(15).

PMID: 34360767 PMC: 8347336. DOI: 10.3390/ijms22158001.


Strongyloides stercoralis and HTLV-1 coinfection in CD34+ cord blood stem cell humanized mice: Alteration of cytokine responses and enhancement of larval growth.

Springer L, Patton J, Zhan T, Rabson A, Lin H, Manser T PLoS Negl Trop Dis. 2021; 15(7):e0009559.

PMID: 34314415 PMC: 8315519. DOI: 10.1371/journal.pntd.0009559.


References
1.
Ito R, Takahashi T, Katano I, Ito M . Current advances in humanized mouse models. Cell Mol Immunol. 2012; 9(3):208-14. PMC: 4012844. DOI: 10.1038/cmi.2012.2. View

2.
Bangham C, Meekings K, Toulza F, Nejmeddine M, Majorovits E, Asquith B . The immune control of HTLV-1 infection: selection forces and dynamics. Front Biosci (Landmark Ed). 2009; 14(8):2889-903. DOI: 10.2741/3420. View

3.
Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J, Lanzavecchia A . Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004; 304(5667):104-7. DOI: 10.1126/science.1093933. View

4.
Morgan O . HTLV-1 associated myelopathy/tropical spastic paraparesis: how far have we come?. West Indian Med J. 2012; 60(5):505-12. View

5.
Biddison W, Kubota R, Kawanishi T, Taub D, Cruikshank W, Center D . Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol. 1997; 159(4):2018-25. View